144514-35-2

Basic information

• Product Name: Propanedioic acid, [3-(3,4-difluorophenyl)-4-methyl-1,3-thiazetidin-2-ylidene]-, diethyl ester
• CAS NO: 144514-35-2
• Molecular Formula: C16H17F2NO4S
• Molecular Weight: 357.378
• Mol File: 144514-35-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Propanedioic acid, [3-(3,4-difluorophenyl)-4-methyl-1,3-thiazetidin-2-ylidene]-, diethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Propanedioic acid, [3-(3,4-difluorophenyl)-4-methyl-1,3-thiazetidin-2-ylidene]-, diethyl ester(144514-35-2)
• EPA Substance Registry System: Propanedioic acid, [3-(3,4-difluorophenyl)-4-methyl-1,3-thiazetidin-2-ylidene]-, diethyl ester(144514-35-2)

Safety Data

• Hazardous Substances Data: 144514-35-2(Hazardous Substances Data)

Upstream product

• 594-02-5 1,1-diiodoethane 
• 3863-11-4 3,4-difluoroaniline 
• 144514-15-8 3,4-difluorophenyl dithiocarbamic acid triethylammonium 
• 113028-75-4 3,4-difluorophenyl isothiocyanate 

Downstream Products

• 123447-62-1 prulifloxacin 
• 113028-17-4 ethyl 6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-4H-(1,3)thiazeto(3,2-a)quinoline-3-carboxylate 
• 112984-60-8 ulifloxacin 
• 113046-72-3 ethyl 6,7-difluoro-1-methyl-4-oxo-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylate 

Relevant articles and documents

STUDIES ON PYRIDONECARBOXYLIC ACIDS. 1. SYNTHESIS AND ANTIBACTERIAL EVALUATION OF 7-SUBSTITUTED-6-HALO-4-OXO-4H-THIAZETOQUINOLINE-3-CARBOXYLIC ACIDS

A series of thiazetoquinoline-3-carboxylic acids and their esters were prepared and evaluated for antibacterial activity.The derivatives with a hydrogen or methyl group at C-1, fluorine at C-6, and piperazinyl or 4-methyl-1-piperazinyl group at C-7 showed superior in vitro antibacterial activity, and the derivatives with 4-methyl-1-piperazinyl group at C-7 had potent in vivo activity.Compound 29a (NM394) showed excellent in vitro antibacterial activity and low toxicity but poor absorption from the gastrointestinal tract.Compound 29ee (NM441), an N- derivative of 29a, was found to possess a favorable pharmacokinetic profile and oral activity superior to that of ciprofloxacin in experimental animals.